NYSE:TEVAPharmaceuticals
How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story
Earlier in January 2026, Teva Pharmaceutical Industries released multi-year guidance through 2030, projecting flat-to-slightly lower revenues in 2026, modest revenue growth thereafter, and significantly higher operating profit, while also securing up to US$500,000,000 in development funding from Royalty Pharma for its anti-IL-15 antibody TEV-‘408.
This combination of clearer long-term profit targets and external funding support for TEV-‘408 underscores management’s confidence in Teva’s...